Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool.
Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool.
Rheumatology (Oxford). 2021 Nov 3;60(11):5271-5281. doi: 10.1093/rheumatology/keab210.
This study aimed to test the performance of the new ACR and EULAR criteria, that include ANA positivity as entry criterion, in JSLE.
Performance of the ACR/EULAR-2019 criteria were compared with Systemic Lupus International Collaborating Clinics (SLICC-2012), using data from children and young people (CYP) in the UK JSLE Cohort Study (n = 482), with the ACR-1997 criteria used as reference standard. An unselected cohort of CYP positive for ANA (n = 129) was used to calculate positive/negative predictive values of the criteria.
At both first and last visits, the number of patients fulfilling the different classification criteria varied significantly (P < 0.001). The sensitivity of the SLICC-2012 criteria was higher when compared with that of the ACR/EULAR-2019 criteria at first and last visits (98% vs 94% for first visit, and 98% vs 96% for last visit; P < 0.001), when all available CYP were considered. The ACR/EULAR-2019 criteria were more specific when compared with the SLICC-2012 criteria (77% vs 67% for first visit, and 81% vs 71% for last visit; P < 0.001). Significant differences between the classification criteria were mainly caused by the variation in ANA positivity across ages. In the unselected cohort of ANA-positive CYP, the ACR/EULAR-2019 criteria produced the highest false-positive classification (6/129, 5%).
In CYP, the ACR/EULAR-2019 criteria are not superior to those of the SLICC-2012 or ACR-1997 criteria. If classification criteria are designed to include CYP and adult populations, paediatric rheumatologists should be included in the consensus and evaluation process, as seemingly minor changes can significantly affect outcomes.
本研究旨在检验包含 ANA 阳性作为纳入标准的新 ACR 和 EULAR 标准在幼年特发性关节炎(JSLE)中的性能。
使用来自英国 JSLE 队列研究的儿童和青少年(CYP)数据(n=482),比较了 ACR/EULAR-2019 标准与系统性红斑狼疮国际合作临床(SLICC-2012)标准的性能,同时使用 ACR-1997 标准作为参考标准。使用ANA 阳性的 CYP 未选择队列(n=129)计算标准的阳性/阴性预测值。
在首次和末次就诊时,满足不同分类标准的患者数量差异显著(P<0.001)。当考虑所有可获得的 CYP 时,SLICC-2012 标准的敏感性高于 ACR/EULAR-2019 标准(首次就诊时为 98%比 94%,末次就诊时为 98%比 96%;P<0.001)。与 SLICC-2012 标准相比,ACR/EULAR-2019 标准的特异性更高(首次就诊时为 77%比 67%,末次就诊时为 81%比 71%;P<0.001)。分类标准之间的显著差异主要是由于 ANA 阳性在不同年龄组之间的变化引起的。在未选择的 ANA 阳性 CYP 队列中,ACR/EULAR-2019 标准产生了最高的假阳性分类(6/129,5%)。
在 CYP 中,ACR/EULAR-2019 标准并不优于 SLICC-2012 或 ACR-1997 标准。如果分类标准旨在纳入 CYP 和成人人群,儿科风湿病学家应参与共识和评估过程,因为看似微小的变化可能会显著影响结果。